‘Global Preventive Vaccines Market, 2020-2030’ (By Roots Analysis)

Posted April 13, 2021 by steffan987

A detailed assessment of the current market landscape, including information on type of developer (industry, non-industry, industry / non-industry)
To order this detailed 250+ page report, please visit this -https://www.rootsanalysis.com/reports/view_document/preventive-vaccines/318.html

Key Inclusions
 A detailed assessment of the current market landscape, including information on type of developer (industry, non-industry, industry / non-industry), phase of development (phase I, phase I/II, phase II, phase II/III, phase III and preregistration) of lead candidates, route of administration (intramuscular, intranasal, oral, intradermal, subcutaneous, intravenous and others), type of vaccine API (live, attenuated vaccine, recombinant vaccine, conjugate vaccine, inactivated vaccine, DNA vaccine, peptide vaccine, subunit vaccine, mRNA vaccine, toxoid vaccine and others), dosage form (ready to use liquid, lyophilized powder, nasal spray, capsule and tablet), dosage (single dose, 2 doses, 3 doses, 4 doses, 5 doses and 6 doses), target disease indication and target patient population (children, adults and seniors).
 A competitiveness analysis of preventive vaccine developers, taking into consideration supplier strength (based on company size and its experience in this field) and pipeline strength (based on the number of clinical-stage vaccine candidates, highest phase of development, number of compatible routes of administration, number of indications evaluated and target patient population).
 Elaborate profiles of the key preventive vaccine developers (shortlisted based on a proprietary criterion) across North America, Europe and Asia Pacific. Each profile includes a brief overview of the company, its year of establishment, location of headquarters, number of employees and financial information (if available). In addition to this, the profile includes information on the various clinical-stage vaccine candidates developed by the company. Further, we have provided the recent developments of the company and an informed future outlook.
 A detailed analysis of more than 1,400 completed, ongoing and planned clinical studies of preventive vaccines, highlighting prevalent trends across various relevant parameters, such as trial registration year, phase of development, trial recruitment status, study design, trial focus area, type of preventive vaccine (based on pathogen), target disease indication(s), type of sponsor / collaborator, leading industry sponsors / collaborators (in terms of number of trials conducted), enrolled patients population and regional distribution.
 An overview of the ongoing vaccine development initiatives for complex conditions, such as COVID-19, Ebola virus disease, HIV/AIDS, malaria and zika virus infection, including information on disease, its global burden, current treatment landscape and preventive vaccine research landscape. Further, we have provided the information on investments made and recent developments in the domain.
 An analysis of the investments made in this domain, during the period between 2015 and 2020 (till March), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are engaged in developing preventive vaccines.
 A case study on contract manufacturing landscape for vaccines, featuring a comprehensive list of active CMOs and analyses based on a number of parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), geographical location, number of vaccine manufacturing facilities, types of services offered (cell / virus banking, analytical development / testing, formulation, process development, fill / finish and regulatory filings), type of expression systems used for vaccine production (mammalian, microbial and others) and type of vaccine manufactured.

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
 Route of Administration
 Intramuscular
 Subcutaneous
 Oral
 Intravenous
 Others

 Type of Vaccine
 Pneumococcal Conjugate Vaccine
 Human Papilloma Virus Vaccine
 Rotavirus Vaccine
 Influenza Vaccine
 MMR Vaccine
 Tetanus and Diphtheria Booster Vaccine
 Varicella Vaccine
 DTaP-Hib-IPV Vaccine
 DTaP-HepB-Hib-IPV Vaccine
 Others

 Type of Vaccine API
 Live, Attenuated Vaccine
 Inactivated Vaccine
 Conjugate Vaccine
 Subunit Vaccine
 Toxoid Vaccine
 Others

 Target Patient Population
 Pediatric Patients
 Adults

 Key Players
 GlaxoSmithKline
 Merck
 Sanofi Pasteur
 Pfizer
 Emergent BioSolutions
 Others

To request sample pages, please visit this - https://www.rootsanalysis.com/reports/318/request-sample.html

Key Questions Answered
 Who are the leading developers of preventive vaccines?
 How big is the development pipeline and which new indications are coming in focus?
 Who are the key investors in the preventive vaccines market?
 What is the impact of COVID-19 on the demand for preventive vaccines?
 Which are the key / emerging CMOs, in different regions, that you can reach out to for your vaccine manufacturing requirements?
 How is the current and future opportunity likely to be distributed across key market segments?

You may also be interested in the following titles:
 Novel coronavirus (COVID-19): Preventive Vaccines, Therapeutics and Diagnostics in Development
 Novel Vaccine Delivery Devices Market, 2019-2030 [COVID-19 SERIES]
 Vaccine Contract Manufacturing Market (2nd Edition), 2019-2030 [COVID-19 SERIES]

Contact Us
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]
-- END ---
Contact Email [email protected]
Issued By Steffan Joe
Phone 0594623595
Business Address 108 strreet
New York
Country Afghanistan
Categories Biotech , Health , Industry
Tags health , pharma , report
Last Updated April 13, 2021